Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

 

Items 1 to 25 of 289 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Catalog#SizeProduct NamePrice
71290-1 50 ug Anti-PD-1 Neutralizing Antibody, PE-labeled
$325.00
33297 100 ml 3x CLTA4 Assay Buffer
$195.00
60540 2 vials ADCC Bioassay Effector Cell F variant (Low Affinity) - Jurkat Recombinant Cell Line Contact us for pricing
60541 2 vials ADCC Bioassay Effector Cell V variant (High Affinity) - Jurkat Recombinant Cell Line Contact us for pricing
60641 20 µg ANPRA/Aequorin Expression vector
$850.00
71209 100 µg Anti-CD20 Antibody
$300.00
71212 100 µg Anti-CTLA4 Neutralizing Antibody
$445.00
71295-1 50 μg Anti-GITR Antibody, PE-labeled
$325.00
71295-2 100 μg Anti-GITR Antibody, PE-labeled
$465.00
91015 100 μg Anti-IL-17A Neutralizing Antibody
$445.00
71219 100 µg Anti-LAG3, Neutralizing Antibody
$445.00
71120 100 µg Anti-PD-1 Neutralizing Antibody
$445.00
71215 100 µg Anti-PD-1 Neutralizing Antibody, Biotin-labeled
$465.00
71290-2 100 ug Anti-PD-1 Neutralizing Antibody, PE-labeled
$465.00
71213 100 µg Anti-PD-L1 (CD274) Neutralizing Antibody
$445.00
71128-1 50 μg Anti-PD-L1 Antibody, PE-labeled
$325.00
71128-2 100 μg Anti-PD-L1 Antibody, PE-labeled
$465.00
71214 100 µg Anti-PD-L1 Neutralizing Antibody, Biotin-labeled
$465.00
71218 100 µg Anti-TIGIT Antibody
$445.00
60612 500 reactions AP1 Reporter Kit (JNK Pathway)
$525.00
60514 500 reactions ARE Reporter Kit (Nrf2 Antioxidant Pathway )
$525.00
72048 384 rxns ARG1 Inhibitor Screening Assay Kit
$995.00
71658 50 μg ARG1, His-Tag
$415.00
71659 50 μg ARG2, His-Tag
$415.00
71125 100 µg B7-1 (CD80), Fc fusion (Human) HiP™
$300.00

Items 1 to 25 of 289 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5